Annual EBITDA
-$274.66 M
+$66.68 M+19.54%
December 31, 2024
Summary
- As of March 13, 2025, SWTX annual EBITDA is -$274.66 million, with the most recent change of +$66.68 million (+19.54%) on December 31, 2024.
- During the last 3 years, SWTX annual EBITDA has fallen by -$101.69 million (-58.78%).
- SWTX annual EBITDA is now -1386.75% below its all-time high of -$18.47 million, reached on December 31, 2018.
Performance
SWTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$80.33 M
-$23.27 M-40.78%
December 31, 2024
Summary
- As of March 13, 2025, SWTX quarterly EBITDA is -$80.33 million, with the most recent change of -$23.27 million (-40.78%) on December 31, 2024.
- Over the past year, SWTX quarterly EBITDA has dropped by -$36.25 million (-82.24%).
- SWTX quarterly EBITDA is now -809.02% below its all-time high of $11.33 million, reached on December 31, 2020.
Performance
SWTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$274.66 M
+$17.60 M+6.02%
December 31, 2024
Summary
- As of March 13, 2025, SWTX TTM EBITDA is -$274.66 million, with the most recent change of +$17.60 million (+6.02%) on December 31, 2024.
- Over the past year, SWTX TTM EBITDA has increased by +$44.05 million (+13.82%).
- SWTX TTM EBITDA is now -5154.70% below its all-time high of -$5.23 million, reached on September 30, 2018.
Performance
SWTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SWTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +19.5% | -82.2% | +13.8% |
| 3 y3 years | -58.8% | -82.2% | +13.8% |
| 5 y5 years | -365.2% | -82.2% | +13.8% |
SWTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -58.8% | +19.5% | -82.2% | +18.0% | -58.8% | +23.1% |
| 5 y | 5-year | -497.4% | +19.5% | -809.0% | +18.0% | -497.4% | +23.1% |
| alltime | all time | -1386.8% | +19.5% | -809.0% | +18.0% | -5154.7% | +23.1% |
SpringWorks Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$274.66 M(-19.5%) | -$80.33 M(+40.8%) | -$274.66 M(-6.0%) |
| Sep 2024 | - | -$57.06 M(+29.5%) | -$292.26 M(-8.3%) |
| Jun 2024 | - | -$44.08 M(-52.7%) | -$318.71 M(-10.8%) |
| Mar 2024 | - | -$93.20 M(-4.8%) | -$357.10 M(+4.6%) |
| Dec 2023 | -$341.35 M(+21.9%) | -$97.92 M(+17.3%) | -$341.35 M(+6.1%) |
| Sep 2023 | - | -$83.50 M(+1.3%) | -$321.62 M(+3.9%) |
| Jun 2023 | - | -$82.47 M(+6.5%) | -$309.64 M(+4.6%) |
| Mar 2023 | - | -$77.45 M(-1.0%) | -$295.99 M(+5.7%) |
| Dec 2022 | -$279.91 M(+61.8%) | -$78.20 M(+9.3%) | -$279.91 M(+8.8%) |
| Sep 2022 | - | -$71.53 M(+3.9%) | -$257.36 M(+13.6%) |
| Jun 2022 | - | -$68.82 M(+12.2%) | -$226.61 M(+10.7%) |
| Mar 2022 | - | -$61.36 M(+10.3%) | -$204.69 M(+18.3%) |
| Dec 2021 | -$172.98 M | -$55.65 M(+36.5%) | -$172.98 M(+63.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$40.78 M(-13.1%) | -$106.00 M(+22.2%) |
| Jun 2021 | - | -$46.91 M(+58.2%) | -$86.72 M(+45.6%) |
| Mar 2021 | - | -$29.65 M(-361.7%) | -$59.56 M(+29.6%) |
| Dec 2020 | -$45.98 M(-22.1%) | $11.33 M(-152.7%) | -$45.98 M(-38.4%) |
| Sep 2020 | - | -$21.50 M(+8.9%) | -$74.61 M(+9.1%) |
| Jun 2020 | - | -$19.75 M(+23.0%) | -$68.38 M(+7.8%) |
| Mar 2020 | - | -$16.06 M(-7.2%) | -$63.44 M(+7.4%) |
| Dec 2019 | -$59.05 M(+219.6%) | -$17.31 M(+13.4%) | -$59.05 M(+22.6%) |
| Sep 2019 | - | -$15.27 M(+3.1%) | -$48.18 M(+26.3%) |
| Jun 2019 | - | -$14.81 M(+26.9%) | -$38.14 M(+63.5%) |
| Mar 2019 | - | -$11.67 M(+81.2%) | -$23.33 M(+100.0%) |
| Dec 2018 | -$18.47 M | -$6.44 M(+23.2%) | -$11.67 M(+123.2%) |
| Sep 2018 | - | -$5.23 M | -$5.23 M |
FAQ
- What is SpringWorks Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics annual EBITDA year-on-year change?
- What is SpringWorks Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics quarterly EBITDA year-on-year change?
- What is SpringWorks Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics TTM EBITDA year-on-year change?
What is SpringWorks Therapeutics annual EBITDA?
The current annual EBITDA of SWTX is -$274.66 M
What is the all time high annual EBITDA for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high annual EBITDA is -$18.47 M
What is SpringWorks Therapeutics annual EBITDA year-on-year change?
Over the past year, SWTX annual EBITDA has changed by +$66.68 M (+19.54%)
What is SpringWorks Therapeutics quarterly EBITDA?
The current quarterly EBITDA of SWTX is -$80.33 M
What is the all time high quarterly EBITDA for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high quarterly EBITDA is $11.33 M
What is SpringWorks Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SWTX quarterly EBITDA has changed by -$36.25 M (-82.24%)
What is SpringWorks Therapeutics TTM EBITDA?
The current TTM EBITDA of SWTX is -$274.66 M
What is the all time high TTM EBITDA for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high TTM EBITDA is -$5.23 M
What is SpringWorks Therapeutics TTM EBITDA year-on-year change?
Over the past year, SWTX TTM EBITDA has changed by +$44.05 M (+13.82%)